Application of arctigenin in preparation of medicine for relieving cardiotoxicity

By reducing cardiomyocyte death and inhibiting apoptosis, the cardiotoxicity caused by doxorubicin is addressed, providing a safer alternative, better than existing dextamide, significantly improving the heart Functional impairment.

CN119015274APending Publication Date: 2024-11-26JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411193440.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The lack of effective strategies in the prior art to prevent or mitigate cardiotoxicity caused by doxorubicin, leading to arrhythmia, ventricular dilation and congestive heart failure, limiting its use in clinical practice, and existing dextropropylene treatments It may reduce anti-tumor efficacy and increase the risk of secondary malignancy.

Method used

Arctigenin (ARC) is used as a drug component to alleviate cardiotoxic effects by reducing cardiomyocyte death, inhibiting apoptosis and reversing cardiac function damage caused by doxorubicin, providing an alternative drug to improve tumor treatment. Safety and patient quality of life.

Benefits of technology

Arctidin significantly inhibits cardiomyocyte damage caused by doxorubicin, reduces cardiotoxicity, and is better than existing dextropropylimine, providing a safer alternative to alleviate the adverse effects of doxorubicin therapy. reaction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015274A_ABST
    Figure CN119015274A_ABST
Patent Text Reader

Abstract

The invention discloses application of arctigenin in preparation of a medicine for relieving cardiotoxicity, and belongs to the technical field of biological medicine. Arctigenin is used for directly treating mouse-derived H9C2 myocardial cells in vitro, and it is found that arctigenin can significantly relieve myocardial cell toxicity phenotypes induced by adriamycin, such as cell death, oxidative stress and the like. Meanwhile, animal experiments prove that the arctigenin can remarkably relieve mouse heart function impairment caused by adriamycin. The arctigenin can be used for preparing the medicine for relieving the doxorubicin-induced cardiotoxicity, and a new way and means are provided for treating the doxorubicin-induced cardiotoxicity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of arctigenin in preparing a medicine for alleviating cardiac toxicity, and belongs to the technical field of biomedicine. Background Art

[0002] In recent years, tumor treatment technologies have developed rapidly. The application of new technologies and new drugs has significantly prolonged the survival of tumor patients. However, the cardiotoxicity caused by tumor treatment drugs has increased the morbidity and mortality of cardiovascular diseases in patients. The anthracycline drug doxorubicin (DOX) is a milestone drug in the development of tumor treatment and has been widely used in clinical practice. However, once DOX was developed and used, it was found to have dose-dependent cardiotoxicity, including various types of arrhythmias and ventricular dilatation, and eventually developed into congestive heart failure. These cardiotoxicities have greatly limited the clinical use of DOX.

[0003] At present, there is no effective strategy to prevent or alleviate DOX-induced cardiotoxicity in clinical practice. The only way to treat it is to strengthen the patient's cardiac function monitoring and reduce the dose of DOX. Dexrazoxane is the only FDA-approved drug for DOX cardiotoxicity. It works by iron chelation and reducing oxidative stress. However, the use of dexrazoxane may lead to reduced anti-tumor efficacy, thereby increasing the risk of secondary malignant tumors. Therefore, exploring alternative drugs has very important clinical scientific significance for improving the safety of tumor treatment and improving the long-term quality of life of patients. Summary of the invention

[0004] The purpose of the present invention is to provide the use of arctigenin (ARC) in the preparation of a drug for alleviating cardiotoxicity, so as to solve the problems existing in the above-mentioned prior art.

[0005] Arctigenin is a lignan found in natural plants such as burdock and forsythia, and has multiple biological activities such as antioxidant and anti-inflammatory. The chemical structure of arctigenin supports free radical scavenging properties. Structure-activity relationship studies have shown that the presence of phenolic hydroxyl and three methoxy groups plays a vital role in its free radical scavenging ability. Arctigenin has a conjugated double bone structure, which further supports its antioxidant properties. Studies have shown that arctigenin has the ability to inhibit NF-κB and downregulate proinflammatory cytokines including TNF-α, interleukin-6 (IL-6) and IL-1β in different disease models. In addition, many studies have shown that arctigenin also has good anti-tumor effects. ARC has high safety and stability in use and has broad application prospects in the field of biomedicine. However, there has been no report on ARC in the treatment or improvement of DOX-induced cardiotoxicity. Therefore, based on the improvement of ARC on DOX-induced cardiotoxicity, the development of new drugs has a bright prospect.

[0006] The present invention finds that arctigenin can significantly inhibit myocardial cell damage caused by adriamycin, such as myocardial cell death and oxidative stress, thereby achieving the effect of alleviating the heart damage caused by adriamycin treatment.

[0007] To achieve the above object, the present invention provides the following solutions:

[0008] The first object of the present invention is to provide the use of arctigenin in preparing a drug for alleviating cardiac toxicity or treating myocardial damage.

[0009] In one embodiment, the molecular formula of arctigenin in the application is: 21 H 24 O6, CAS number: 7770-78-7.

[0010] In one embodiment, the cardiotoxic effect in said use is caused by doxorubicin.

[0011] In one embodiment, the cardiotoxicity includes, but is not limited to, cardiomyocyte death, myocardial injury, decreased cardiac contractility, and heart failure.

[0012] In one embodiment, the myocardial injury in said use is caused by doxorubicin.

[0013] In one embodiment, the arctigenin achieves the effect of treating myocardial damage and alleviating cardiac toxicity by reducing cardiomyocyte death, inhibiting cell apoptosis and alleviating impaired cardiac function.

[0014] In one embodiment, the reduction of cardiomyocyte cell death includes but is not limited to reducing the release of cardiomyocyte LDH and the generation of ROS.

[0015] In one embodiment, the inhibition of cell apoptosis includes but is not limited to reversing the changes in the levels of apoptosis-related proteins BAX and BCL2 induced by doxorubicin and reducing the BAX / BCL2 ratio.

[0016] In one embodiment, the reduction of impaired cardiac function includes but is not limited to reversing doxorubicin-induced decreases in left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS).

[0017] In one embodiment, the dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.

[0018] The second object of the present invention is to provide a drug capable of alleviating cardiotoxicity or treating myocardial damage, wherein the active ingredient of the drug comprises arctiin.

[0019] In one embodiment, the molecular formula of arctigenin in the drug is: 21 H 24 O6, CAS number: 7770-78-7.

[0020] In one embodiment, the cardiotoxic effect or myocardial injury is caused by doxorubicin.

[0021] In one embodiment, the drug treats myocardial damage and alleviates cardiotoxic effects by reducing cardiomyocyte death, inhibiting cell apoptosis, and alleviating impaired cardiac function.

[0022] In one embodiment, the drug contains the above-mentioned drug ingredients and pharmaceutically acceptable excipients.

[0023] In one embodiment, the auxiliary material includes any one of a carrier, a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an emulsifier, a solubilizer, a solubilizing agent, an osmotic pressure regulator, a surfactant, a coating material, a colorant, a pH regulator, an antioxidant, an antibacterial agent or a buffer, or a combination of at least two thereof.

[0024] In one embodiment, the carrier is one or more of a virus, a liposome, and a nanoparticle.

[0025] In one embodiment, the excipient is one or more of mannitol, lactose, fatty acid, and polyethylene glycol.

[0026] In one embodiment, the dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.

[0027] In one embodiment, the administration route of the drug includes oral administration, sublingual administration, rectal administration, skin mucosal administration, inhalation administration or injection administration.

[0028] In one embodiment, the drug of the present invention has at least one or more of the following functions:

[0029] (1) Promote cell viability, reduce the release of LDH, and reduce cell death.

[0030] (2) Reverse the changes in the levels of apoptosis-related proteins BAX and BCL2 caused by doxorubicin, reduce the BAX / BCL2 ratio, and inhibit cell apoptosis.

[0031] (3) Reduce the production of ROS in doxorubicin-induced cellular oxidative stress and alleviate cytotoxicity.

[0032] (4) Reduce the cardiac function damage caused by doxorubicin and reverse the decrease in left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS) caused by doxorubicin.

[0033] Beneficial effects:

[0034] The application of arctiin provided by the present invention in the preparation of a drug for alleviating cardiotoxicity is the first to discover that arctiin can effectively alleviate myocardial damage caused by cardiotoxicity. The present invention confirms through cell experiments that arctiin can inhibit myocardial cell death caused by doxorubicin; at the same time, the present invention also confirms through animal experiments that arctiin can alleviate the cardiac function damage of mice caused by the action of doxorubicin. The cell experiments and animal experiments of the present invention prove that arctiin can alleviate the cardiotoxicity caused by doxorubicin, and the effect is better than that of dexamethasone, which provides a theoretical basis for arctiin to replace dexamethasone and alleviate the adverse reactions caused by doxorubicin in anti-tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0036] Figure 1 The results of the CCK8 experiment to detect cell viability. CON is the blank control group, without arctigenin and doxorubicin; DOX is the 1μM doxorubicin treatment group; DOX+ARC is the 1μM doxorubicin and 1, 2.5, 5, 10, 20 and 40μM arctigenin treatment groups;

[0037] Figure 2 The results of the cell LDH release experiment. LDH: lactate dehydrogenase. CON is the blank control group, without arctigenin and doxorubicin; DOX is the 1μM doxorubicin treatment group; DOX+ARC is the 1μM doxorubicin and 5, 10 and 20μM arctigenin treatment groups;

[0038] Figure 3 The results of the Calcein AM&PI experiment in H9C2 cardiomyocytes are shown in Figure 1. CON is the blank control group, DOX is the 1μM doxorubicin treatment group, DOX+5μM ARC is the 1μM doxorubicin and 5μM arctigenin treatment group, and DOX+10μM ARC is the 1μM doxorubicin and 10μM arctigenin treatment group.

[0039] Figure 4 The figure is the statistical result of relative fluorescence intensity of Calcein AM staining. CON is the blank control group, without arctiin and doxorubicin; DOX is the 1μM doxorubicin treatment group; DOX+ARC is the 1μM doxorubicin and 5 and 10μM arctiin treatment groups respectively;

[0040] Figure 5 The figure shows the statistical results of the relative fluorescence intensity of PI staining. CON is the blank control group, without arctigenin and doxorubicin; DOX is the 1 μM doxorubicin treatment group; DOX+ARC is the 1 μM doxorubicin and 5 and 10 μM arctigenin treatment groups respectively;

[0041] Figure 6 The results of western blot detection of BAX and BCL2, BAX and BCL2 are apoptosis-related proteins. CON is the blank control group, DOX is the 1μM doxorubicin treatment group, DOX+5μM ARC is the 1μM doxorubicin and 5μM arctigenin treatment group, and DOX+10μM ARC is the 1μM doxorubicin and 10μM arctigenin treatment group;

[0042] Figure 7 The statistical graph of the relative expression of BAX protein. CON is the blank control group, without arctigenin and doxorubicin; DOX is the 1 μM doxorubicin treatment group; DOX+ARC is the 1 μM doxorubicin and 5 and 10 μM arctigenin treatment groups;

[0043] Figure 8 The statistical graph of the relative expression of BCL2 protein. CON is the blank control group, without arctigenin and doxorubicin; DOX is the 1 μM doxorubicin treatment group; DOX+ARC is the 1 μM doxorubicin and 5 and 10 μM arctigenin treatment groups;

[0044] Fig. 9 The figure is a statistical chart of the relative expression of BAX and BCL2 proteins. CON is a blank control group without arctiin and doxorubicin; DOX is a 1 μM doxorubicin treatment group; DOX+ARC is a 1 μM doxorubicin and 5 and 10 μM arctiin treatment groups;

[0045] Fig.10 The figure shows the ROS fluorescence observation results of H9C2 cardiomyocytes. Among them, CON is the blank control group, DOX is the 1μM doxorubicin treatment group, DOX+5μM ARC is the 1μM doxorubicin and 5μM arctigenin treatment group, and DOX+10μM ARC is the 1μM doxorubicin and 10μM arctigenin treatment group;

[0046] Fig.11 The figure shows the statistical results of the relative fluorescence intensity of ROS staining. CON is the blank control group, without arctigenin and doxorubicin; DOX is the 1 μM doxorubicin treatment group; DOX+ARC is the 1 μM doxorubicin and 5 and 10 μM arctigenin treatment groups respectively;

[0047] Fig.12 These are ultrasound images of the hearts of mice in different treatment groups. CON is the blank control group; DOX is the doxorubicin treatment group; LARC is the doxorubicin treatment and low-dose arctiin treatment group; HARC is the doxorubicin treatment and high-dose arctiin treatment group; DEX is the doxorubicin treatment and dexrazoxane treatment group;

[0048] Fig.13 The statistical results of left ventricular ejection fraction (EF) detected by cardiac ultrasound in mice in different treatment groups. CON is the blank control group; DOX is the doxorubicin treatment group; LARC is the doxorubicin treatment and low-dose arctiin treatment group; HARC is the doxorubicin treatment and high-dose arctiin treatment group; DEX is the doxorubicin treatment and dexrazoxane treatment group;

[0049] Fig.14 The statistical results of left ventricular short axis shortening fraction (FS) detected by cardiac ultrasound in mice in different treatment groups. CON is the blank control group; DOX is the doxorubicin treatment group; DOX+LARC is the doxorubicin treatment and low-dose arctiin treatment group; DOX+HARC is the doxorubicin treatment and high-dose arctiin treatment group; DOX+DEX is the doxorubicin treatment and dexrazoxane treatment group. DETAILED DESCRIPTION

[0050] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0051] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0052] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0053] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0054] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0055] Unless otherwise specified, the experimental materials and drugs used in the embodiments of the present invention can be obtained through conventional purchase.

[0056] Arctigenin used in the present invention has the molecular formula: 21 H 24 O6, CAS number: 7770-78-7.

[0057] 1. Experimental materials and drugs involved in the following examples:

[0058] DMEM medium, fetal bovine serum, exosome-free serum, 0.25% trypsin, and Hochest 33342 stain were purchased from Gibco, USA;

[0059] PBS buffer and 4% paraformaldehyde were purchased from Wuhan Saiweier;

[0060] Calcein AM & PI staining kit was purchased from Japan Dojin Chemical;

[0061] LDH detection kit and cell ROS detection kit were purchased from Bio-Tech Biotechnology;

[0062] CCK8 detection reagent and western blot color development kit were purchased from Nanjing Novozymes;

[0063] H9C2 cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences;

[0064] Experimental drugs such as depilatory cream and isoflurane anesthetic can be purchased through regular channels;

[0065] Experimental instruments and materials such as carbon dioxide incubator, biological safety cabinet, microplate reader, confocal microscope, VEVO3100LT small animal high-frequency ultrasound imaging system, culture dishes, Pasteur pipettes, centrifuge tubes, abalone counting plates, pipette guns, disposable pipette tips, 96-well plates, 6-well plates, etc. can all be purchased through regular channels.

[0066] 2. Data statistics methods involved in the following embodiments:

[0067] The experiment was repeated three times independently. The data of the repeated experiments were averaged and expressed as mean ± standard deviation (SD). Statistical analysis was performed using Graphpad Prism 10.0 software. The t-test was used to determine the differences between the two groups, and analysis of variance (ANOVA) was used for multiple group comparisons. The Turkey method after ANOVA was used to analyze the comparisons between the groups. P < 0.05 was considered statistically significant. ** is P < 0.01, *** is P < 0.001, and **** is P < 0.0001.

[0068] Example 1: Cell experiment confirms that arctigenin alleviates the cardiomyocyte toxicity induced by doxorubicin

[0069] 1. Trypsinization of cells

[0070] Before cell manipulation, open the biosafety cabinet for UV sterilization for 30 minutes, preheat the cell culture medium (DMEM) and trypsin in a 37°C water bath, and spray all items with 75% alcohol for disinfection before entering the biosafety cabinet.

[0071] First, discard the culture medium in the culture dish and wash H9C2 cells twice with PBS buffer. Add 1 mL of trypsin to each culture dish and digest for 2 minutes in a 37°C incubator. After the cells become round, add 1 mL of fresh culture medium to terminate digestion. Finally, repeatedly blow and beat until the cells on the culture dish fall off, collect the detached cells in a 15 mL centrifuge tube, and centrifuge at 1000×g for 3 minutes.

[0072] 2. Counting cells with abalone counting chamber

[0073] After centrifugation, discard the culture medium in the centrifuge tube, add fresh culture medium and mix by pipetting repeatedly. Use a pipette to transfer 10 μL of cell suspension to the edge of one side of the blood cell counting plate, so that the cell suspension is evenly distributed in the counting plate, and repeat the same operation to evenly fill the counting chamber on the other side. Place the cell counting plate on the microscope stage, find the field of view under the 10x microscope, and then switch to the 20x microscope for counting. Follow the principle of counting the cells on the top but not the bottom, and count the cells on the left but not the right, and count the total number of cells in the 4 large squares. After the counting on one side is completed, follow the same method to count the total number of cells on the other side. After the counting is completed, calculate the total number of cells. The calculation formula is as follows:

[0074] Cell number = total number of cells counted / number of large squares × dilution factor × 10 4 .

[0075] 3. CCK8 detection of cell viability

[0076] 6 × 10 cells were plated per well in a 96-well plate. 4 cells and placed in the incubator for 24 hours. The culture medium in the wells was discarded, the PBS buffer was gently rinsed twice, and 100 μL of complete culture medium containing arctigenin (concentrations of 1, 2.5, 5, 10, 20 and 40 μM) and doxorubicin (concentrations of 0 and 1 μM) was added to each well, and 4 replicates were made for each concentration. That is, the CON group did not contain arctigenin and doxorubicin; the DOX group contained only doxorubicin at a concentration of 1 μM; the DOX+DRC group contained doxorubicin at a concentration of 1 μM and arctigenin at concentrations of 1, 2.5, 5, 10, 20 and 40 μM, respectively. After being placed in the incubator for 24 hours, the culture medium in the wells was discarded, the PBS buffer was gently rinsed twice, 90 μL of complete culture medium was added, and 10 μL of CCK8 detection reagent was added to each well, and the wells were incubated in the incubator for 2.5 hours, and the absorbance at 480 nm was measured using an enzyme reader.

[0077] Cell CCK8 test results Figure 1 As shown. Figure 1 It can be seen that the cell viability of the DOX+ARC group was significantly higher than that of the DOX group. Furthermore, the cell viability of the ARC dose of 10-40μM increased nearly two times compared with the DOX group. The results showed that arctigenin had a significant protective effect on the viability of H9C2 cardiomyocytes treated with doxorubicin.

[0078] 4. Cellular LDH Release Detection

[0079] 6 × 10 cells were plated per well in a 96-well plate. 4Cells were placed in an incubator for 24 hours. The culture medium in the wells was discarded, and the PBS buffer was gently rinsed twice. 100 μL of complete culture medium containing arctigenin (concentrations of 0, 5, 10, and 20 μM) and doxorubicin (concentrations of 0 and 1 μM) were added to each well, and 4 replicates were made for each concentration. That is, the CON group did not contain arctigenin and doxorubicin; the DOX group contained only doxorubicin at a concentration of 1 μM; the DOX+DRC group contained doxorubicin at a concentration of 1 μM and arctigenin at concentrations of 5, 10, and 20 μM, respectively. After being placed in the incubator for 24 hours, the upper culture medium was aspirated and the LDH (lactate dehydrogenase) content was detected using an LDH detection kit.

[0080] The results of cell LDH release assay were as follows Figure 2 As shown. Figure 2 It can be seen that after treatment with doxorubicin, the release of cell LDH increased significantly by about 1.8 times. After treatment with arctigenin, the release of LDH decreased significantly, and cell death decreased, approaching the level of the control group.

[0081] 5. Calcein AM & PI staining experiment

[0082] 7 × 10 cells were plated per well in a 12-well plate. 5 cells and cultured in an incubator for 24 hours. The culture medium in the well plate was discarded, and the well plate was gently rinsed twice with PBS buffer. 1 mL of complete culture medium containing arctiin (concentrations of 0, 5, and 10 μM) and doxorubicin (concentrations of 0 and 1 μM) was added to each well, and 4 replicate wells were made for each concentration. That is, the CON group did not contain arctiin and doxorubicin; the DOX group contained only doxorubicin at a concentration of 1 μM; the DOX+DRC group contained doxorubicin at a concentration of 1 μM and arctiin at concentrations of 5 and 10 μM, respectively. Incubate in an incubator for 24 hours, discard the culture medium, and rinse twice with PBS buffer; add Calcein AM&PI detection reagent and 1×Hochest 33342 to each well, incubate in an incubator away from light for 15 minutes, discard the staining solution, wash 3 times with PBS buffer, observe under a fluorescence microscope, and calculate the fluorescence intensity with Image J.

[0083] The results of the cell Calcein AM & PI staining experiment are as follows Figure 3 to Figure 5 As shown. The statistical results of relative fluorescence intensity of Calcein AM staining and PI staining showed that after doxorubicin treatment, the number of live cells in H9C2 cardiomyocytes decreased and the number of dead cells increased, while the number of live cells in H9C2 cardiomyocytes treated with arctiin increased and the number of dead cells decreased. The best effect was achieved when the arctiin dose was 10 μM, and the number of live cells increased by nearly two times compared with the DOX group.

[0084] 6. Western Blot

[0085] (1) Electrophoresis

[0086] Refer to the kit instructions to prepare 10% separation gel. Wash the H9C2 cells after drug treatment twice with pre-cooled PBS, add an appropriate volume of RIPA lysis buffer (containing protease inhibitors) and lyse the cells on ice for 30 minutes to ensure complete cell lysis. Then collect the lysis supernatant, centrifuge at 12000rpm and 4℃ for 15 minutes, and finally add the collected protein supernatant sample to 5× loading buffer, and dilute all samples to the same concentration, heat in a 100℃ metal bath for 10 minutes to fully denature the protein. Add the samples to the gel wells in turn, keep the voltage at 100V, and electrophoresis for 80 minutes.

[0087] (2) Transfer

[0088] According to the size of the gel, cut a 0.22μm PVDF membrane of the same size, use the wet transfer method, and set the transfer conditions to a constant current of 300mA for 60min. After the transfer, place the membrane directly in the prepared 5% milk, shake it slowly on a shaker, and block it at room temperature. After 2h, discard the milk, add TBST buffer, shake and wash for 10min, a total of 3 times.

[0089] (3) Primary antibody incubation

[0090] Refer to the instructions of the primary antibody and dilute the antibody with antibody diluent at a ratio of 1:1000. Use filter paper to remove water stains on the protein band, add the diluted primary antibody, and incubate overnight at 4°C. After the end, add TBST buffer and wash on a shaker for 10 minutes, a total of 3 times.

[0091] (4) Secondary antibody incubation

[0092] Refer to the secondary antibody instructions and dilute the horseradish peroxidase (HRP) labeled secondary antibody with antibody diluent at a ratio of 1:6000. Use filter paper to absorb the liquid on the surface of the strip, place it in the diluted secondary antibody, and incubate slowly at room temperature on a shaker for 1 hour.

[0093] Recover the secondary antibody, add TBST buffer, and wash on a shaker for 10 min, for a total of 3 times.

[0094] (5) Protein detection

[0095] The ECL exposure solution was evenly distributed on the strips and incubated for 1 min. The exposure was performed using the Tianneng chemiluminescence gel imaging system / all-purpose imager, and the results were processed using Image J.

[0096] The results of Western blotting of cells are as follows Figure 6 to Figure 9 As shown. Figure 6 to Figure 9It can be seen that after doxorubicin treatment, the level of pro-apoptotic protein BAX increased significantly by 1.5 times, the level of anti-apoptotic protein BCL2 decreased significantly by 50%, and the BAX / BCL2 ratio increased significantly by about 2.5 times. The above results show that cell apoptosis increased. After arctigenin treatment, the level of cell BAX decreased significantly by more than 30%, the level of BCL2 increased significantly by 40-50%, and the BAX / BCL2 ratio decreased significantly by 100%, indicating that cell apoptosis was inhibited.

[0097] 7. Cellular ROS detection experiment

[0098] 7 × 10 cells were plated per well in a 12-well plate. 5 cells and cultured in an incubator for 24 hours. The culture medium in the well plate was discarded, and the well plate was gently rinsed twice with PBS buffer. 1 mL of complete culture medium containing arctigenin (concentrations of 0, 5, and 10 μM) and doxorubicin (concentrations of 0 and 1 μM) was added to each well, and 4 replicates were made for each concentration. That is, the CON group did not contain arctigenin and doxorubicin; the DOX group contained only doxorubicin at a concentration of 1 μM; the DOX+DRC group contained doxorubicin at a concentration of 1 μM and arctigenin at concentrations of 5 and 10 μM, respectively. Incubate in an incubator for 24 hours, discard the culture medium, and rinse twice with PBS buffer; add ROS detection reagent and 1×Hochest 33342 to each well, incubate in an incubator away from light for 20 minutes, discard the staining solution, wash 3 times with PBS buffer, observe with a fluorescence microscope, and calculate the fluorescence intensity with Image J.

[0099] The results of the cell ROS detection experiment are as follows Figure 10-11 As shown. Figure 10-11 It can be seen that compared with the DOX group, the ROS generation in the DOX+ARC group was reduced by more than 50%. Therefore, arctigenin can significantly reduce the generation of cell oxidative stress (ROS) induced by doxorubicin and alleviate the cytotoxicity induced by doxorubicin.

[0100] Example 2: Animal experiments verify that arctigenin alleviates the cardiotoxicity induced by doxorubicin

[0101] 1. Experimental Animal Grouping

[0102] Thirty 6-8 week old C57BL / 6J mice were randomly divided into groups, 6 mice in each group, each weighing about 22 g, and fed for 4 weeks. They were: CON group, doxorubicin (DOX) group, DOX+low dose arctiin (LARC) group, DOX+high dose arctiin (HARC) group, and DOX+dexrazoxane (DEX) group. After grouping, intraperitoneal injection or gavage was performed according to the experimental requirements, and the specific injection volume / gavage volume was calculated according to the actual weight of the mice.

[0103] The doxorubicin, arctigenin and dexrazoxane solution was prepared as follows:

[0104] Doxorubicin (5 mg / kg): weigh 5 mg of doxorubicin and dissolve it in 10 mL of normal saline to obtain a doxorubicin solution with a concentration of 0.5 mg / mL.

[0105] Arctiin low dose (20 mg / kg): Weigh 10 mg of arctiin and dissolve it in 5 mL of normal saline to obtain an arctiin solution with a concentration of 2 mg / mL.

[0106] High dose of arctiin (40 mg / kg): Weigh 20 mg of arctiin and dissolve it in 5 mL of normal saline to obtain an arctiin solution with a concentration of 4 mg / mL.

[0107] Dexrazoxane (50 mg / kg): The instructions for clinical injection of dexrazoxane indicate that the recommended dose is 10:1 (500 mg dexrazoxane: 50 mg doxorubicin). Therefore, a dose of 50 mg / kg was selected. Weigh 50 mg dexrazoxane and dissolve it in 10 mL of normal saline to obtain a dexrazoxane solution with a concentration of 5 mg / mL.

[0108] The experimental animals were divided into the following groups:

[0109] Control (CON) group: about 0.2 mL of sterile PBS solution was injected intraperitoneally once a week, and about 0.2 mL of normal saline was gavaged daily.

[0110] Doxorubicin (DOX) group: about 0.2 mL of 0.5 mg / mL DOX solution was injected intraperitoneally once a week.

[0111] DOX+low-dose arctiin (LARC) group: about 0.2 mL of 0.5 mg / mL DOX solution was intraperitoneally injected once a week; about 0.2 mL of 2 mg / mL arctiin solution was gavaged once a day.

[0112] DOX+high-dose arctiin (HARC) group: about 0.2 mL of 0.5 mg / mL DOX solution was intraperitoneally injected once a week; about 0.2 mL of 4 mg / mL arctiin solution was gavaged once a day.

[0113] DOX+dexrazoxane (DEX) group: about 0.2 mL of 5 mg / mL dexrazoxane solution was intraperitoneally injected; about 0.2 mL of 0.5 mg / mL DOX solution was intraperitoneally injected.

[0114] 2. Cardiac ultrasound examination

[0115] The mouse was placed in an anesthesia device with a flow rate of 1L / min and filled with 3-5% isoflurane and 100% oxygen. Anesthesia was induced for 1-2 minutes until the mouse fell. The hair on the mouse's neck and chest was removed using a depilatory cream to expose the position of the mouse's heart, and the mouse was fixed supine on a constant temperature plate. The flow rate was maintained at 0.6L / min, 1.5% isoflurane anesthesia, and ultrasonic coupling agent was applied to the mouse's heart. When the mouse's heart rate was maintained at 350-450bpm, M-mode ultrasound images were recorded. The mouse's left ventricular ejection fraction (EF) and left ventricular short axis shortening fraction (FS) were detected, and all test results were based on three consecutive cardiac cycles.

[0116] The results of mouse heart ultrasound examination are as follows Figure 12 to Figure 14 As shown. Figure 12 to Figure 14 It can be seen that after the mice were treated with 20 mg / mL of doxorubicin, the left ventricular ejection fraction (EF) and the left ventricular short axis shortening fraction (FS) were significantly reduced, while the EF and FS were significantly increased after gavage with arctiin, indicating that arctiin significantly improved the cardiac contractile function and alleviated the cardiac function damage caused by doxorubicin in mice. The addition of a high dose of arctiin (40 mg / kg) increased the left ventricular ejection fraction by nearly two times, and the shortening rate of the left ventricle in the short axis direction was reduced by more than two times compared with DOX, close to the normal index. And the effect of high-dose arctiin on improving cardiac contractile function is better than that of dexamethasone.

[0117] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. Application of arctigenin in the preparation of drugs for alleviating cardiotoxicity or treating myocardial damage.

2. The use according to claim 1, characterized in that: The molecular formula of arctigenin in the application is: C 21 H 24 O6, CAS number: 7770-78-7.

3. The use according to claim 1, characterized in that: The cardiotoxic effect or myocardial damage is caused by doxorubicin.

4. The use according to claim 1, characterized in that: The cardiotoxicity includes, but is not limited to, cardiomyocyte death, myocardial damage, decreased cardiac contractility and heart failure.

5. The use according to claim 1, characterized in that: The arctigenin achieves the effects of treating myocardial damage and alleviating cardiac toxicity by inhibiting myocardial cell death, reducing cell apoptosis and alleviating cardiac function damage.

6. The drug according to claim 1, characterized in that The administration methods of the drug include oral administration, sublingual administration, rectal administration, skin and mucosal administration, inhalation administration or injection administration.

7. The drug according to claim 1, characterized in that The drug includes pharmaceutically acceptable excipients.

8. The drug according to claim 1, characterized in that The dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.

9. A drug capable of alleviating cardiotoxicity or treating myocardial damage, characterized in that: The active ingredient of the drug contains arctigenin.

10. The drug according to claim 9, characterized in that The cardiotoxic effect or myocardial damage is caused by doxorubicin.